Wire Stories

LESSENGERS Demonstrates 800G QSFP-DD and 400G QSFP112 Optical Transceivers

BASEL, Switzerland--(BUSINESS WIRE)--LESSENGERS Inc. (�LESSENGERS�), an innovative optical interconnect solution provider, announced today, a live demonstration of polymer-wired 800G QSFP-DD…

3 years ago

India Over The Counter Drug Market to Grow at 7.85% Through 2028 – ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "India Over The Counter Drug Market, By Product Type, By Route of Administration, By Dosage Form, By Distribution…

3 years ago

J.P. Morgan to Acquire Renovite Technologies, Inc.

Acquisition of cloud-native payments technology firm to modernize infrastructure and create greater flexibility for the firm�s merchant acquiring capabilities globally…

3 years ago

The international conference to discuss innovation, the key to solving global warming with experts from industry, academia, and government from…

3 years ago

Cellusion and Celregen, a member of Fosun Pharma, Enter into Exclusive License Agreement of CLS001 for a Corneal Endothelial Cell Regenerative Therapy in the Greater China Region

Celregen Obtains the Exclusive Rights to Develop, Manufacturing and Commercialize CLS001 in Greater China Region; Cellusion Retains Other Regional Rights.…

3 years ago

The partnership will help boost contact center employee morale and provide superior customer experiences using Conversational AI and Automation HO…

3 years ago

Chery Is Accompanied With Love at the Mid-Autumn Festival

WUHU, China--(BUSINESS WIRE)--China celebrates the Mid-Autumn Festival on September 10. On this day, all Chinese families will partake in eating…

3 years ago

DESTINY-Lung02 phase 2 trial shows clinically meaningful efficacy and favorable safety at 5.4 mg/kg dose versus 6.4 mg/kg dose of…

3 years ago

DS-7300 Continues to Show Promising Durable Response in Patients with Several Types of Advanced Cancer

Extended follow-up data from phase 1/2 trial of DS-7300 in patients with metastatic lung, prostate or esophageal cancer to be…

3 years ago

BeiGene Announces Data Presentations at ESMO 2022 Including Late-Breaking Oral Presentation for Tislelizumab in First-Line Unresectable Hepatocellular Cancer

Tislelizumab demonstrated non-inferiority for overall survival and favorable safety profile versus sorafenib in global Phase 3 trial Additional poster presentations…

3 years ago